Prognostic model for second progression-free survival and overall survival in patients with high-risk metastatic hormone-sensitive prostate cancer treated with abiraterone acetate and androgen deprivation therapy.
Narita S, Yanagisawa T, Hatakeyama S, Hata K, Fujita K, Ueda T, Tanaka T, Maita S, Chiba S, Sato H, Sekine Y, Kobayashi M, Kashima S, Yamamoto R, Numakura K, Saito M, Takayama K, Okane K, Ishida T, Horikawa Y, Kumazawa T, Shimoda J, Iwabuchi I, Suzuki T, Ukimura O, Kimura T, Ohyama C, Nomura K, Habuchi T.
Narita S, et al. Among authors: horikawa y.
Prostate. 2025 Jan;85(1):73-81. doi: 10.1002/pros.24802. Epub 2024 Sep 30.
Prostate. 2025.
PMID: 39344365